Introduction
Recent studies have linked chronic exposure to pentosan polysulfate (PPS; Elmiron [Janssen Pharmaceuticals, Titusville, NJ]) with the development of a pigmentary maculopathy. 1, 2 PPS is the only Food and Drug Administration (FDA) -approved oral medicine for the treatment of interstitial cystitis (IC). 3, 4 This case highlights the importance of careful review of past medical histories and medication profiles of all patients, particularly those with retinal and imaging findings suggestive of a dystrophic process. Failure to diagnose a medication toxicity in a timely fashion may lead to preventable irreversible vision loss. Furthermore, inappropriate diagnosis of a retinal dystrophy may lead to unwarranted genetic counseling and ill-informed life and family planning.
Case report
A 41-year-old white female presented for a second opinion regarding a recent diagnosis of Stargardt disease. She complained of darkening of her vision, and progressive difficulty with reading and night vision. Her past medical history was positive for Crohn's disease, hypothyroidism, chronic interstitial cystitis, irritable bowel syndrome, and bipolar disorder. Relevant medications included adalimumab, methotrexate, gabapentin, quetiapine, naratriptan, oxcarbazepine, topiramate, and pentosan polysulfate (PPS).
Her best corrected visual acuity was 20/25 OD and 20/20 OS.
Anterior segments were normal. Her dilated fundus exam demonstrated severe retinal pigment epithelial abnormalities (RPE) in both eyes, with clumps of hyper-pigmentation within larger areas of hypo-pigmentation that spanned the entire macula and circumferential peri-papillary area ( Fig. 1 
Discussion
It was felt that negative genetic testing, along with atypical clinical and imaging characteristics, rendered Stargardt disease an unlikely diagnosis. Her fundus was suggestive of a pattern dystrophy. However, the broad extent and symmetry of abnormalities were uncharacteristic. Pharmacy records were reviewed and indicated that she had been dispensed 11,500 capsules of PPS (Elmiron [Janssen Pharmaceuticals, Titusville, NJ]) over 18 years. Her prescription was for 400mg daily, which resulted in a possible cumulative exposure of 1150 g. Two recent publications detailed the clinical and imaging characteristics of patients with long term exposure to PPS. 1, 2 As our patient fit the reported toxicity profile, we made the diagnosis of maculopathy due to long term PPS exposure. We asked her to contact her urologist to discontinue the drug, as this maculopathy may be progressive and/or may evolve into vision-threatening geographic atrophy. 1, 2 
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